Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Ryvu Therapeutics S.A. (RVU.WA)
PLN15.30
-0.28 (-1.80%)
PL WSE Healthcare Biotechnology
Address
Leona Henryka Sternbacha 2 30-394
Kraków, PL
Kraków, PL
CEO
Pawel Tadeusz Przewiezlikowski
Website
ryvu.com
IPO
2011-07-14
ISIN PLSELVT00013
Description
Ryvu Therapeutics S.A. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing novel small molecule treatments for oncology. Their primary experimental drug, RVU120, functions as a CDK8 kinase inhibitor and shows promise for development across hematological malignancies and solid tumors. This compound is presently in a Phase 1b clinical study for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Among their other assets is SEL24/MEN1703, a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group, which is currently undergoing a Phase 2 clinical trial for acute myeloid leukemia. Furthermore, Ryvu's earlier research pipeline explores candidates in areas such as kinases, cancer metabolism, synthetic lethality, and immuno-oncology. The company, established in 2007, is based in Kraków, Poland.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
PLN15.30
-0.28 (-1.80%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
49.0K
Beta
0.40
Float Shares
15.76M
Free Float %
68.2%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.92% | -21.09% | -27.52% | -32.05% | -38.33% | -36.06% | -44.89% | -70.48% | -67.79% | -22.81% | +221.48% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
15.30
Ratings Trend (MoM)
60% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 3 | 0 |
| Hold | 2 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-0.92
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
0 / 10
No MOAT
Composite Rating
D+
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-20.2% Q1'26: +0.1% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+9.1% Q1'26: +54.5% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-274.5% Q1'26: -138.8% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-196.2% Q1'26: -60.3% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-683.3% Q1'26: -113.9% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+0.0% ★ Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.64× Q1'26: -2.28× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 4 Rev. Ana. 2 EPS Ana. |
Dec 2027 3 Rev. Ana. 2 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. |
Dec 2030 1 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
41.03M
est: 55.43M (-26.0%)
|
48.13M
est: 71.32M (-32.5%)
|
87.82M
est: 105.99M (-17.1%)
|
77.21M
est: 104.25M (-25.9%)
|
42.57M
est: 112.39M (-62.1%)
|
15.41M
est: 35.10M (-56.1%)
|
11.19M
est: 26.00M (-57.0%)
|
38.80M
est: 135.30M (-71.3%)
|
46.86M
est: 82.39M (-43.1%)
|
77.97M
est: 98.08M (-20.5%)
|
62.25M
est: 84.18M (-26.0%)
|
157.73M
75.98M – 236.57M
+87.4% YoY
|
120.23M
98.74M – 159.48M
-23.8% YoY
|
652.00M
389.31M – 939.49M
+442.3% YoY
|
81.00M
48.37M – 116.72M
-87.6% YoY
|
162.00M
96.73M – 233.43M
+100.0% YoY
|
| EBITDA |
5.56M
est: -55.43M (+110.0%)
|
2.48M
est: -71.32M (+103.5%)
|
17.88M
est: -105.99M (+116.9%)
|
-17.26M
est: -104.25M (+83.4%)
|
-35.72M
est: -112.39M (+68.2%)
|
-17.87M
est: -35.10M (+49.1%)
|
-65.96M
est: -26.00M (-153.7%)
|
-65.21M
est: -135.30M (+51.8%)
|
-81.04M
est: -82.39M (+1.6%)
|
-96.83M
est: -98.08M (+1.3%)
|
-112.71M
est: -84.18M (-33.9%)
|
-157.73M
-236.57M – -75.98M
-87.4% YoY
|
-120.23M
-159.48M – -98.74M
+23.8% YoY
|
-652.00M
-939.49M – -389.31M
-442.3% YoY
|
-81.00M
-116.72M – -48.37M
+87.6% YoY
|
-162.00M
-233.43M – -96.73M
-100.0% YoY
|
| EBIT |
2.85M
est: -55.43M (+105.1%)
|
-1.22M
est: -71.32M (+98.3%)
|
9.83M
est: -105.99M (+109.3%)
|
-22.79M
est: -104.25M (+78.1%)
|
-43.71M
est: -112.39M (+61.1%)
|
-30.23M
est: -35.10M (+13.9%)
|
-78.52M
est: -26.00M (-202.0%)
|
-78.11M
est: -135.30M (+42.3%)
|
-92.02M
est: -82.39M (-11.7%)
|
-107.33M
est: -98.08M (-9.4%)
|
-122.15M
est: -84.18M (-45.1%)
|
-157.73M
-236.57M – -75.98M
-87.4% YoY
|
-120.23M
-159.48M – -98.74M
+23.8% YoY
|
-652.00M
-939.49M – -389.31M
-442.3% YoY
|
-81.00M
-116.72M – -48.37M
+87.6% YoY
|
-162.00M
-233.43M – -96.73M
-100.0% YoY
|
| Net Income |
6.27M
est: 7.52M (-16.6%)
|
2.72M
est: 5.65M (-51.9%)
|
6.41M
est: 12.10M (-47.1%)
|
-106.3K
est: 892.9K (-111.9%)
|
-36.00M
est: -22.02M (-63.4%)
|
-31.69M
est: -45.55M (+30.4%)
|
-79.08M
est: -95.95M (+17.6%)
|
-83.78M
est: 3.80M (-2,302.5%)
|
-92.11M
|
-111.44M
est: -104.87M (-6.3%)
|
-101.23M
est: -107.62M (+5.9%)
|
-7.23M
-23.93M – 35.95M
+93.3% YoY
|
-8.79M
-10.51M – -7.06M
-21.6% YoY
|
258.24M
120.02M – 396.47M
+3,039.4% YoY
|
—
— – —
-100.0% YoY
|
—
— – —
|
| SGA |
8.76M
est: 11.79M (-25.7%)
|
10.54M
est: 15.17M (-30.5%)
|
17.94M
est: 22.55M (-20.4%)
|
26.23M
est: 22.18M (+18.3%)
|
4.37M
est: 23.91M (-81.7%)
|
5.47M
est: 7.47M (-26.8%)
|
4.33M
est: 5.53M (-21.7%)
|
5.56M
est: 28.78M (-80.7%)
|
5.67M
est: 12.59M (-55.0%)
|
4.50M
est: 14.99M (-70.0%)
|
3.43M
est: 12.86M (-73.3%)
|
24.10M
11.61M – 36.15M
+87.4% YoY
|
18.37M
15.09M – 24.37M
-23.8% YoY
|
99.63M
59.49M – 143.56M
+442.3% YoY
|
12.38M
7.39M – 17.84M
-87.6% YoY
|
24.76M
14.78M – 35.67M
+100.0% YoY
|
| EPS |
0.48
est: 0.33 (+47.7%)
|
0.20
est: 0.24 (-18.2%)
|
0.48
est: 0.52 (-8.3%)
|
-0.01
est: 0.04 (-117.9%)
|
-2.25
est: -0.95 (-136.2%)
|
-1.89
est: -1.97 (+4.1%)
|
-4.31
est: -4.15 (-3.9%)
|
-4.57
est: 0.17 (-2,774.1%)
|
-4.02
|
-4.82
est: -4.44 (-8.6%)
|
-4.38
est: -4.66 (+5.9%)
|
0.26
-1.04 – 1.56
+105.6% YoY
|
-0.38
-0.45 – -0.31
-246.2% YoY
|
10.90
5.19 – 17.15
+2,968.4% YoY
|
—
— – —
-100.0% YoY
|
—
— – —
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-26 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-25 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-119.35M
OE per share TTM
-5.23
Owner's Yield
-29.74%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
187.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 2 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.01% | 40.5K | 0.65% |
| 2 | State Street SPDR Portfolio Europe ETF SPEU | 0.00% | 1.5K | 0.07% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-372.4K
Shares Outstanding
23.12M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Vatnak Vat-Ho | Chief Business Officer & Member of Management Board | 2M | male |
| Hendrik Nogai | Chief Medical Officer & Member of Management Board | 2M | — |
| Krzysztof Daniel Brzózka | Executive Vice President, Chief Scientific Officer & VP of the Management Board | 1M | — |
| Kamil Sitarz | Chief Operating Officer & Member of the Management Board | 1M | — |
| Pawel Tadeusz Przewiezlikowski | Founder, President of the Management Board & Chief Executive Officer | 457.7K | male |
| Paulina Wolanin | Human Resources Manager | — | female |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for RVU.WA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
